Immatics NV (IMTX)
9.56
+0.10
(+1.06%)
USD |
NASDAQ |
Sep 04, 16:00
9.54
-0.02
(-0.21%)
After-Hours: 20:00
Immatics Research and Development Expense (Quarterly) : 72.57M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 72.57M |
| March 31, 2026 | 69.24M |
| December 31, 2025 | 57.78M |
| September 30, 2025 | 55.13M |
| June 30, 2025 | 51.13M |
| March 31, 2025 | 44.11M |
| December 31, 2024 | 44.64M |
| September 30, 2024 | 42.74M |
| June 30, 2024 | 37.91M |
| March 31, 2024 | 34.85M |
| December 31, 2023 | 35.78M |
| September 30, 2023 | 33.18M |
| June 30, 2023 | 29.73M |
| March 31, 2023 | 29.59M |
| December 31, 2022 |
| Date | Value |
|---|---|
| September 30, 2022 | |
| June 30, 2022 | 26.84M |
| March 31, 2022 | 28.21M |
| December 31, 2021 | 26.24M |
| September 30, 2021 | 25.02M |
| June 30, 2021 | 24.50M |
| March 31, 2021 | 27.76M |
| December 31, 2020 | 24.86M |
| September 30, 2020 | 20.42M |
| June 30, 2020 | 18.18M |
| March 31, 2020 | 13.49M |
| December 31, 2019 | 13.43M |
| September 30, 2019 | 11.38M |
| June 30, 2019 | 10.95M |
| March 31, 2019 | 9.072M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| MediGene AG | -- |
| InflaRx NV | 5.510M |
| BioNTech SE | 514.38M |
| Moderna, Inc. | 588.00M |
| Intellia Therapeutics, Inc. | 80.50M |